The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10364 malaria professionals are enjoying the free benefits of MalariaWorld today

efficacy

A Plasmodium vivax experimental human infection model for evaluating the efficacy of interventions

February 22, 2020 - 16:32 -- Open Access
Author(s): 
Collins KA, Wang CY, Adams M, Mitchell H, Robinson GJ, Rampton M, Elliott S, Odedra A, Khoury DS, Ballard E, Shelper TB, Lucantoni L, Avery VM, Chalon S, Möhrle JJ, McCarthy JS
Reference: 
J Clin Invest. 2020 Feb 11. pii: 134923

Interventions that interrupt Plasmodium vivax transmission or eliminate dormant P. vivax liver-stage parasites will be essential for malaria elimination. Development of these interventions has been hindered by the lack of P. vivax in vitro culture and could be accelerated by a safe and reproducible clinical model in malaria-naïve individuals.

NOT Open Access | Ex vivo efficacy of selective chalcone derivatives on reference strains and field isolates of Plasmodium falciparum

January 14, 2020 - 12:12 -- NOT Open Access
Author(s): 
Dable MT, Tano KD, Ouattara M, Silue KD, Menan EIH, Yavo W
Reference: 
Pathogens and Global Health, 2020 Jan 7:1-5

The extension of Plasmodium falciparum resistance to existing antimalarial drugs is worrying. Faced with this problem, the search for new and effective molecules is necessary. In this context, six chalcone derivatives (B1, B11, B14, B17, SCA02 and SCA03) were tested on field isolates and then reference strains to evaluate their antiplasmodial activity by using the Rieckmann semi-microtest, recommended by WHO, for in vitro and ex vivo activity tests.

In vivo/ex vivo efficacy of artemether–lumefantrine and artesunate–amodiaquine as first-line treatment for uncomplicated falciparum malaria in children: an open label randomized controlled trial in Burkina Faso

January 7, 2020 - 15:14 -- Open Access
Author(s): 
Moussa Lingani, Léa Nadège Bonkian, Halidou Tinto, et al.
Reference: 
Malaria Journal 2020 19:8, 6 January 2020

Artemisinin-based combination therapy (ACT) is recommended to improve malaria treatment efficacy and limit drug-resistant parasites selection in malaria endemic areas. 5 years after they were adopted, the efficacy and safety of artemether–lumefantrine (AL) and artesunate–amodiaquine (ASAQ), the first-line treatments for uncomplicated malaria were assessed in Burkina Faso.

Monitoring of efficacy, tolerability and safety of artemether–lumefantrine and artesunate–amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Lambaréné, Gabon: an open-label clinical trial

December 17, 2019 - 16:46 -- Open Access
Author(s): 
Bayode R. Adegbite, Jean R. Edoa, Ayola A. Adegnika, et al.
Reference: 
Malaria Journal 2019 18:424, 16 December 2019

Malaria remains a major public health problem, affecting mainly low-and middle-income countries. The management of this parasitic disease is challenged by ever increasing drug resistance. This study, investigated the therapeutic efficacy, tolerability and safety of artemether–lumefantrine (AL) and artesunate–amodiaquine (AS–AQ), used as first-line drugs to treat uncomplicated malaria in Lambaréné, Gabon.

The efficacy of dihydroartemisinin-piperaquine and artemether-lumefantrine with and without primaquine on Plasmodium vivax recurrence: A systematic review and individual patient data meta-analysis

October 15, 2019 - 15:36 -- Open Access
Author(s): 
Robert J. Commons, Julie A. Simpson, Ric N. Price, et al.
Reference: 
PLoS Med 16(10): e1002928

Artemisinin-based combination therapy (ACT) is recommended for uncomplicated Plasmodium vivax malaria in areas of emerging chloroquine resistance. We undertook a systematic review and individual patient data meta-analysis to compare the efficacies of dihydroartemisinin-piperaquine (DP) and artemether-lumefantrine (AL) with or without primaquine (PQ) on the risk of recurrent P. vivax.

Medical Condition: 
Subscribe to RSS - efficacy